Description: Endonovo Therapeutics, Inc., formerly Hanover Portfolio Acquisitions, Inc., is a biotechnology company developing a bioelectronic approach to regenerative medicine. The Company operates through two segments: intellectual property licensing and commercialization, and biomedical research and development, which includes development of its square wave form device. Its Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and cell death. Its Cytotronics platform is being developed to create biologically potent cell therapies. It is using this technology to create a therapy for the treatment of Graft-Versus-Host Disease (GvHD), a rare complication following allogeneic tissue transplants. Its Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.
Home Page: www.endonovo.com
6320 Canoga Avenue
Woodland Hills,
CA
91367
United States
Phone:
800 489 4774
Officers
| Name | Title |
|---|---|
| Mr. Alan Brian Collier | Chairman, CEO, Interim CFO & Sec. |
| Mr. Don Calabria | VP of Operations |
| Mr. Garry Michael Kann | Head of Corp. Devel. |
| Mr. Ira Weisberg | Pres & Chief Commercial Officer of Medical Division |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 202.4239 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |